{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:30:50Z","timestamp":1792189850070,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.arr.2026.103151","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:50:41Z","timestamp":1777333841000},"page":"103151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Serious side effects of Alzheimer\u2019s immunotherapy demand scrutiny"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-2367","authenticated-orcid":false,"given":"Poul F.","family":"H\u00f8ilund-Carlsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasan","family":"Andalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph J.","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"de Girolamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos K.","family":"Robakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano L.","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Vissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 12","key":"10.1016\/j.arr.2026.103151_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/brain\/aww194","article-title":"Brain networks under attack: robustness properties and the impact of lesions","volume":"139","author":"Aerts","year":"2016","journal-title":"Brain"},{"issue":"20","key":"10.1016\/j.arr.2026.103151_bib2","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.arr.2026.103151_bib3","article-title":"Amyloid positron emission tomography imaging at the onset of amyloid-related abnormalities with Edema in an Alzheimer's disease patient","volume":"17","author":"Arai","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.arr.2026.103151_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnene.2013.00013","article-title":"FDG-PET imaging in mild traumatic brain injury: a critical review","volume":"5","author":"Byrnes","year":"2014","journal-title":"Front. Neuroenerget."},{"issue":"1","key":"10.1016\/j.arr.2026.103151_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11307-006-0073-0","article-title":"\"Magnetic resonance imaging negative positron emission tomography positive\" temporal lobe epilepsy: FDG-PET pattern differs from mesial temporal lobe epilepsy","volume":"9","author":"Carne","year":"2007","journal-title":"Mol. Imaging Biol."},{"issue":"2","key":"10.1016\/j.arr.2026.103151_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-221305","article-title":"Neuropathology of anti-amyloid-\u03b2 immunotherapy: a case report","volume":"93","author":"Castellani","year":"2023","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.arr.2026.103151_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.arr.2026.103151_bib8","unstructured":"DeShaw, A., 2025. Medical Imaging such as MRI and CT does not detect 80% of brain damage including in advanced CTE. https:\/\/www.deshawlaw.com\/blog\/medical-imaging-such-as-mri-and-ct-do-not-detect-severe-brain-damage-including-in-advanced-cte (accessed 20 February 2026)."},{"issue":"7","key":"10.1016\/j.arr.2026.103151_bib9","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0319-23.2024","article-title":"Lecanemab and donanemab as therapies for Alzheimer's disease: an illustrated perspective on the data","volume":"11","author":"Espay","year":"2024","journal-title":"eNeuro"},{"issue":"9","key":"10.1016\/j.arr.2026.103151_bib10","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.arr.2026.103151_bib11","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1162\/jocn_a_00222","article-title":"Focal brain lesions to critical locations cause widespread disruption of the modular organization of the brain","volume":"24","author":"Gratton","year":"2012","journal-title":"J. Cogn. Neurosci."},{"issue":"7","key":"10.1016\/j.arr.2026.103151_bib12","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/ijms25073892","article-title":"Alzheimer's amyloid hypothesis and antibody therapy: melting glaciers?","volume":"25","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103151_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/13872877261417548","article-title":"Serious doubts about amyloid-\u03b2 (A\u03b2) biomarkers and anti-A\u03b2 immunotherapy","author":"H\u00f8ilund-Carlsen","year":"2026","journal-title":"J. Alzheimers Dis. Online First"},{"key":"10.1016\/j.arr.2026.103151_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101996","article-title":"Passive Alzheimer's immunotherapy: a promising or uncertain option?","volume":"90","author":"H\u00f8ilund-Carlsen","year":"2023","journal-title":"Ageing Res Rev."},{"issue":"1","key":"10.1016\/j.arr.2026.103151_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.yacr.2024.04.013","article-title":"Hybrid PET\/MRI in neurodegenerative disorders","volume":"6","author":"Keir","year":"2024","journal-title":"Adv. Clin. Radiol."},{"issue":"2","key":"10.1016\/j.arr.2026.103151_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-230099","article-title":"The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes","volume":"94","author":"Kepp","year":"2023","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.arr.2026.103151_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1089\/neu.2018.5641","article-title":"Cerebral glucose metabolism in patients with chronic mental and cognitive sequelae after a single blunt mild traumatic brain injury without visible brain lesions","volume":"36","author":"Komura","year":"2019","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.arr.2026.103151_bib18","doi-asserted-by":"crossref","first-page":"q2010","DOI":"10.1136\/bmj.q2010","article-title":"Donanemab: conflicts of interest found in FDA Committee that approved new Alzheimer's drug","author":"Lenzer","year":"2024","journal-title":"Bmj 386"},{"key":"10.1016\/j.arr.2026.103151_bib19","unstructured":"Medicinr\u00e5det, 2025. Medicinr\u00e5det anbefaler ikke nyt l\u00e6gemiddel til patienter med Alzheimers sygdom. https:\/\/medicinraadet.dk\/nyheder\/2025\/medicinradet-anbefaler-ikke-nyt-laegemiddel-til-patienter-med-alzheimers-sygdom (accessed 21 Februrary 2026)."},{"issue":"5","key":"10.1016\/j.arr.2026.103151_bib20","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer's disease: Rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.arr.2026.103151_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","article-title":"Cell death","volume":"187","author":"Newton","year":"2024","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.arr.2026.103151_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.arr.2026.103151_bib23","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.arr.2026.103151_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2176\/nmc.ra.2016-0293","article-title":"Disorder of Executive function of the brain after head injury and mild traumatic brain injury - neuroimaging and diagnostic criteria for implementation of administrative support in Japan","volume":"57","author":"Shinoda","year":"2017","journal-title":"Neurol. Med Chir."},{"key":"10.1016\/j.arr.2026.103151_bib25","unstructured":"Sigal Law Firm, 2026. How Do You Prove A Traumatic Brain Injury That Isn\u2019t Visible On An MRI Or CT Scan? \u3008https:\/\/www.sigallaw.com\/blog\/how-to-prove-traumatic-brain-injury-not-visible-on-mri-ct-scan\/\u3009 (accessed 1 April 2026)."},{"issue":"6","key":"10.1016\/j.arr.2026.103151_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.arr.2026.103151_bib27","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.arr.2026.103151_bib28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.arr.2026.103151_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3174\/ajnr.A5929","article-title":"FDG-PET and MRI in the evolution of new-onset refractory status epilepticus","volume":"40","author":"Strohm","year":"2019","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.arr.2026.103151_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"10.1016\/j.arr.2026.103151_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2026.103151_bib32","unstructured":"Wilshire Law Firm, 2026. How Do You Prove a Traumatic Brain Injury in Court? A Complete Guide for California Victims. https:\/\/wilshirelawfirm.com\/blog\/how-do-you-prove-a-traumatic-brain-injury-in-court\/ (accessed 1 April 2026)."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:47:22Z","timestamp":1780516042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163726001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["S1568163726001431"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2026.103151","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious side effects of Alzheimer\u2019s immunotherapy demand scrutiny","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2026.103151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103151"}}